Navigation Links
Phase 3 Results Show Canagliflozin as Add-On Therapy to Metformin and Pioglitazone Significantly Lowers Blood Sugar Levels in Adult Patients with Type 2 Diabetes
Date:11/9/2012

research, and these results further support the efficacy and safety profile of canagliflozin," said Kirk Ways, M.D., Ph.D., Vice President and Compound Development Team Leader for canagliflozin at Janssen. "The data are in line with the Phase 3 results announced earlier this year at the annual meetings of the American Diabetes Association and European Association for the Study of Diabetes which suggest that canagliflozin could help control blood glucose in a wide range of patients with type 2 diabetes, including patients on other antihyperglycemic medications such as pioglitazone and metformin."

These results are included in the abstract, "Efficacy and Safety of Canagliflozin in Subjects with Type 2 Diabetes on Metformin and Pioglitazone" (board #64). An additional abstract, "Efficacy and Safety of Canagliflozin in Subjects with Type 2 Diabetes with Moderate Renal Impairment" (board #75) will also be presented at CODHy 2012.

About Canagliflozin

Canagliflozin is an investigational sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of patients with type 2 diabetes. The kidneys of people with type 2 diabetes reabsorb greater amounts of glucose back into the body compared to non-diabetic people, which may contribute to elevated glucose levels. Canagliflozin blocks the reabsorption of glucose by the kidney, increasing glucose excretion and lowering blood glucose levels.

The global Phase 3 canagliflozin clinical program, which enrolled 10,285 patients in nine studies, is the largest late-stage development program for an investigational pharmacologic product for the treatment of type 2 diabetes submitted to health authorities to date. The program evaluated the safety and efficacy of canagliflozin across the spectrum of type 2 diabetes management, from adult patients treated only with diet and exercise to those requiring insulin injections to maintain glycemic control, and in three large studies in special populations: older p
'/>"/>

SOURCE Janssen Research & Development, LLC
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
2. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
3. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
4. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
5. Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
6. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
7. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
8. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
9. Results Reported for Phase Ib Open-Label Clinical Trial for the Treatment of Depression Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
10. Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD
11. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 23, 2013  Omeros Corporation (NASDAQ: ... Drug Application (IND) to evaluate OMS824 in Huntington,s ... and Drug Administration (FDA). OMS824 selectively inhibits phosphodiesterase ... the brain linked to a wide range of ... schizophrenia. OMS824 has shown promising results in animal ...
(Date:5/23/2013)... 2013 SynCardia Systems, Inc. ( www.syncardia.com ), ... Canada and CE ( Europe ) approved ... Centre in Scotland , which boasts ... SynCardia temporary Total Artificial Heart powered by the ... Bodyworks Exhibition, one of the most advanced exhibitions of ...
(Date:5/23/2013)... May 23, 2013  PAREXEL International Corporation (NASDAQ: ... presenting at the Jefferies Healthcare Conference in New York.  ... and Chief Financial Officer, will be making a presentation ... on Monday, June 3, 2013. A live ... "Investors" section of PAREXEL,s website at www.PAREXEL.com ...
Breaking Medicine Technology:Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 2Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 3Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 4Glasgow Science Centre Features SynCardia Total Artificial Heart in $3 Million Exhibition 2Glasgow Science Centre Features SynCardia Total Artificial Heart in $3 Million Exhibition 3PAREXEL International To Present At Jefferies Healthcare Conference 2
... The U.S. Food and Drug Administration today approved ... to blood transfusions in patients with thalassemia, a genetic ... response to prior chelation therapy. (Logo: ... have excess iron in the body from the frequent ...
... Reata Pharmaceuticals, Inc. announced Friday a significant expansion ... program, bardoxolone methyl, and to continue advancing its earlier-stage ... executives: Paul Audhya, MD, as Vice ... Hilary Malone, Ph.D., as Vice President and Chief Regulatory ...
Cached Medicine Technology:FDA Approves Ferriprox to Treat Patients with Excess Iron in the Body 2FDA Approves Ferriprox to Treat Patients with Excess Iron in the Body 3Reata Pharmaceuticals Adds Executives to Management Team and Board of Directors 2Reata Pharmaceuticals Adds Executives to Management Team and Board of Directors 3
(Date:5/23/2013)... 2013 Cheap Concert Tickets announces that ... 2013 at stadiums throughout North America. This well known ... McCartney concert tickets to help McCartney fans see Sir Paul ... Tickets, states that she is also offering the customer appreciation ... Being a baby boomer, she is also a huge McCartney ...
(Date:5/23/2013)... THURSDAY, May 23 (HealthDay News) -- The sensation of ... be traced back to a small molecule released in ... mice. Researchers say this molecule, known as ... through the central nervous system. Ultimately, this signal is ... humans and mice are similar, the researchers concluded that ...
(Date:5/23/2013)... HealthDay Reporter , , THURSDAY, May 23 (HealthDay News) -- ... badly as methamphetamine or crack cocaine, a new study ... mouth, or ,coke mouth, it is startling to see ... the same," said Dr. Mohamed Bassiouny, a professor of ... in Philadelphia. Methamphetamine, crack cocaine and soda -- ...
(Date:5/23/2013)... Chinese and U.S. scientists have used virus isolated from ... to determine whether the virus could infect and be ... mammalian model in influenza research, and efficient transmission of ... how well the same process might occur in people. ... Institute of Allergy and Infectious Diseases, part of the ...
(Date:5/23/2013)... 23, 2013 Special Learning, Inc., ... educational resources for the autism, Down syndrome and ... opening its first global autism treatment center and ... August. This new world-class program is the first ... evidence-based practices to treat and deliver exceptional education ...
Breaking Medicine News(10 mins):Health News:Paul McCartney Tickets: Prices Slashed on Paul McCartney Tickets in Austin, Brooklyn, Tulsa, Memphis Washington DC, Milwaukee, Boston, Indianapolis, Regina and Seattle 2Health News:Got an Itch? Mouse Study May Help Explain Why 2Health News:Diet Soda Habit as Bad for Teeth as Meth Addiction, Study Claims 2Health News:Diet Soda Habit as Bad for Teeth as Meth Addiction, Study Claims 3Health News:Ferrets, pigs susceptible to H7N9 avian influenza virus 2Health News:Special Learning, Inc. to Expand its Services for Individuals with Special Needs with Opening of New Special Education School in the Philippines 2Health News:Special Learning, Inc. to Expand its Services for Individuals with Special Needs with Opening of New Special Education School in the Philippines 3
... SOUTH EASTON, Mass., March 10 Pressure,BioSciences, Inc. ... has moved its,corporate offices to 14 Norfolk Avenue ... accommodate the Company,s transition from an,early-stage, research and ... Schumacher, PBI,s Founder, President, and CEO,commented: "We now ...
... CT System Brings More Innovative Diagnostics to the ... ... March 10 Encouraged by the outstanding,marketing success of the worldwide ... ) announces the 510(k) market clearance of four,new applications aimed at ...
... bone damage and stunted growth , , MONDAY, March 10 ... may place pediatric patients at risk for bone damage ... new red flag concerns a signal transduction inhibitor (STI) ... medulloblastoma brain tumors by short-circuiting tumor growth on the ...
... University of Michigan Health System have found a key ... discovery that lends new insight into fibromyalgia, an often-baffling ... found, pain decreased when levels of the brain molecule ... which appears in the journal Arthritis and Rheumatism, could ...
... Donation Helps Provide Free Surgical Treatments for Children ... Operation Smile, a,worldwide children,s medical charity, today announced ... part of a ,sharing smiles, campaign,from Windows Live. ... physical,examinations and surgical treatment to children in 26 ...
... A study by the Woolcock Institute of Medical Research in ... very mild or well-controlled asthma, regular treatment with low dose ... , The study published in this months edition of Primary ... and compared the effects of inhaled corticosteroids (ICS) and placebo ...
Cached Medicine News:Health News:Pressure BioSciences, Inc. Announces Move to New Corporate Offices 2Health News:Siemens Introduces New Dual Energy Applications to SOMATOM Definition 2Health News:Siemens Introduces New Dual Energy Applications to SOMATOM Definition 3Health News:Siemens Introduces New Dual Energy Applications to SOMATOM Definition 4Health News:New Drug for Brain Cancer Too Dangerous for Pediatric Patients 2Health News:New Drug for Brain Cancer Too Dangerous for Pediatric Patients 3Health News:Pain in fibromyalgia is linked to changes in brain molecule 2Health News:Windows Live $500,000 Donation Commemorates Operation Smile's 25th Anniversary 2Health News:Treatment for mild asthma leads to improved lung function 2
... The Hub Cap Limited ... to provide outstanding fixation and ... targeted solution for four corner ... the plate offers the kind ...
... cornerstones of the Acutrak family are the ... Together they are used primarily for secure ... upper extremity, but have been used for ... stabilized with these two systems have ranged ...
... decade KMI® revolutionized the wrist arthroplasty market ... Wrist System. We're at it again, with ... the Universal2. Like the original, the Universal2 ... live with debilitating arthritis. To date, we ...
A straight suture punch with 2.5 mm needle and 2/0 to #1 monofilament suture....
Medicine Products: